COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients

COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究

基本信息

项目摘要

Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 is a global pandemic. While most COVID-19 cases are mild or moderate, severe cases (~15%) require hospitalization, critical cases (~5%) require intensive care, and many deaths occur. Males, Blacks and Hispanics are at greater risk for COVID-19 infection, and poor prognosis is predicted by older age, race/ethnicity, and prior underlying medical conditions. A potentially critical factor not yet studied is heavy alcohol use or alcohol use disorder (AU/AUD). AU/AUD could increase the risk for COVID-19 infection and poor prognosis through poor health behaviors, by direct effects of alcohol on the immune system, or by indirect effects due to the greater prevalence of underlying medical conditions that predict poor COVID-19 prognosis. Little is known about the relationship of AU/AUD to the likelihood of COVID-19 vaccination, infection, or poor prognosis, and if these relationships are modified by medical conditions (e.g., hypertension, obesity, diabetes), spatially-defined socioenvironmental or exposure variables (e.g., county poverty or COVID-19 rates) or demographic characteristics (sex, age, race/ethnicity, poverty). To study this, large databases are needed that include AU/AUD, demographic characteristics, spatial identifiers, diagnostic, treatment and mortality information. Responding to PA-20-195 (and addressing issues in NOT-AA-20-011), we will utilize the Veterans Administration (VA) Electronic Medical Record (EMR) system for this purpose. The VA treats 6.3 million veterans a year. VA patients have high rates of COVID-19 vulnerability factors, e.g., male, older age, chronic medical conditions. A VA Shared Data Resource identifies COVID-19 cases (now N=186,174, with 9,299 deaths). The many VA patients with ICD-10-CM AUD or positive alcohol (AUDIT-C) screens provide extensive data on whether the likelihood of COVID-19 outcomes differ by AU/AUD status. Leveraging a research infrastructure established in an existing project, we propose a 2-year study to comprehensively address the relationship of AU/AUD to COVID-19 vaccination, infection and prognosis, and how these relationships are affected by demographic, medical, spatial exposure characteristics. Aim1: Determine the relationship of AU/AUD to COVID-19 vaccination, infection, and in those infected, poor prognosis (e.g., hospitalization, ICU treatment, death). Aim 2: Determine if associations of AU/AUD with COVID-19 outcomes vary over time, medical conditions (e.g., hypertension, obesity, diabetes), spatial exposures or demographic characteristics. In Year 01, we will analyze EMR diagnostic, treatment, and vital status death data, using a 12-month lookback period to determine AU/AUD and medical conditions that preceded COVID-19 outcome variables. In Year 02, we will incorporate National Death Index data to examine causes of death, and expand information on veterans ≥age 65 with Medicare data. Logistic regression will evaluate differences in COVID-19 outcomes by AU/AUD status. Among those with COVID-19, survival models will determine if time to poor prognosis events differs by AU/AUD. Results will fill major gaps in knowledge about the risks for and prognosis of COVID-19 among those with AU/AUD.
由SARS-CoV-2引起的2019冠状病毒病(COVID-19)是一种全球性大流行疾病。而大多数COVID-19

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEBORAH S HASIN其他文献

DEBORAH S HASIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEBORAH S HASIN', 18)}}的其他基金

COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients
COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究
  • 批准号:
    10371482
  • 财政年份:
    2022
  • 资助金额:
    $ 18.72万
  • 项目类别:
Scientific Conferences for The College on Problems of Drug Dependence (CPDD)
药物依赖问题学院科学会议(CPDD)
  • 批准号:
    10610865
  • 财政年份:
    2021
  • 资助金额:
    $ 18.72万
  • 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
  • 批准号:
    10393578
  • 财政年份:
    2019
  • 资助金额:
    $ 18.72万
  • 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
  • 批准号:
    10612385
  • 财政年份:
    2019
  • 资助金额:
    $ 18.72万
  • 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints - Administrative Supplement
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点 - 行政补充
  • 批准号:
    10228425
  • 财政年份:
    2016
  • 资助金额:
    $ 18.72万
  • 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
  • 批准号:
    9440313
  • 财政年份:
    2016
  • 资助金额:
    $ 18.72万
  • 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
  • 批准号:
    9883624
  • 财政年份:
    2016
  • 资助金额:
    $ 18.72万
  • 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
  • 批准号:
    9317400
  • 财政年份:
    2014
  • 资助金额:
    $ 18.72万
  • 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
  • 批准号:
    8731034
  • 财政年份:
    2014
  • 资助金额:
    $ 18.72万
  • 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
  • 批准号:
    8932642
  • 财政年份:
    2014
  • 资助金额:
    $ 18.72万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了